For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

By Dr. Priyom Bose, Ph.D. Nearly half of patients with type 2 diabetes and two-thirds without discontinue GLP-1 receptor ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

as prior studies have reported GLP-1 receptor agonist discontinuation rates of up to 81%, Emanuel's group wrote. They added that the links between weight loss and discontinuation and between ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Winfrey opened up about her decision to use a medication to help her lose weight in an interview with People. Her new TV ...